Enhancing TCR-T Activity through Target Selection, Synthetic Biology, & Non-Viral Gene Editing for Solid Tumor Treatment
Time: 1:30 pm
day: DAY ONE TRACK 2 B
Details:
- Discuss how targeting oncodriver mutations for which the cancer has established genetic dependency can limit tumor escape and avoid on-target/off-tumor toxicities
- Highlight the incorporation of novel chimeric fusion proteins that can enable TCR-Ts to overcome unfavorable solid tumor microenvironments
- Discuss the added benefit of non-viral gene-editing to improve the anti-tumor activity and manufacturing of TCR-Ts
